Mar 10 (Reuters) - Esperion Therapeutics Q4 net income USD 61.831 million vs. IBES estimate USD 70 million.
- Q4 operating expenses USD 83.213 million
- Q4 operating income USD 85.233 million vs. IBES estimate USD 98.7 million
- Q4 basic EPS USD 0.26
Mar 10 (Reuters) - Esperion Therapeutics Q4 net income USD 61.831 million vs. IBES estimate USD 70 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.